melanoma-overexpressed antigen 1 (31-44)

Melanoma-overexpressed antigen 1 (31-44) is a synthetic peptide fragment derived from the melanoma-associated antigen MELOE-1, specifically encompassing amino acid residues 31 through 44 of the parent protein. As a research peptide, it represents a defined epitope within a tumor-associated antigen that has garnered significant attention in cancer immunology and tumor antigenicity studies. The sequence is frequently investigated for its immunogenic properties, with particular relevance to melanoma biology and antigen-specific immune response research. Its precise sequence and defined length make it a valuable tool for dissecting peptide-MHC interactions, T-cell recognition, and the broader study of antigen processing and presentation in malignant contexts.

Epitope mapping: The defined sequence of this peptide facilitates high-resolution epitope mapping in studies aimed at characterizing T-cell responses to MELOE-1. By providing a discrete region of the antigen, researchers can assess the specificity and avidity of T-cell clones, enabling the identification of immunodominant regions within the full-length protein. This approach is instrumental for unraveling the mechanisms underlying antigen recognition and for delineating the minimal peptide sequences required for T-cell activation.

T-cell activation assays: Owing to its role as a recognized T-cell epitope, the peptide is widely utilized in functional assays designed to evaluate antigen-specific T-cell responses. In vitro stimulation of peripheral blood mononuclear cells (PBMCs) or isolated T-cell populations with this peptide allows for the quantification of cytokine release, proliferation, and cytotoxic activity. Such studies are essential for understanding the immunological landscape of melanoma and for gauging the potency of immune responses elicited by defined peptide antigens.

Antigen presentation studies: The peptide serves as a model substrate for investigating antigen processing and presentation by major histocompatibility complex (MHC) molecules. Its use in peptide-loading experiments with antigen-presenting cells enables detailed analysis of MHC-peptide binding affinity, stability, and the molecular determinants governing T-cell receptor engagement. These insights support the rational design of peptide-based immunological tools and enhance understanding of the cellular mechanisms that underpin tumor immune surveillance.

Peptide-based vaccine research: As a representative segment of a tumor-associated antigen, this peptide is frequently incorporated into preclinical studies exploring peptide-based vaccine formulations. Its defined sequence allows for controlled evaluation of immunogenicity, adjuvant compatibility, and delivery strategies in experimental models. Such research aids in optimizing peptide selection and formulation parameters for potential immunotherapeutic strategies targeting melanoma antigens.

Immunological reagent development: The peptide is also used as a calibrator or standard in the development of immunological reagents, such as peptide-MHC tetramers and antibody-based detection tools. By serving as a well-characterized target, it enables the validation and quality control of reagents intended for the detection and quantification of antigen-specific T-cell populations. This application supports the advancement of immunomonitoring technologies and facilitates the standardization of assays across research laboratories.

1. Characterization of Novel P-Selectin Targeted Complement Inhibitors in Murine Models of Hindlimb Injury and Transplantation

2. Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics

3. Cationic cell-penetrating peptides are potent furin inhibitors

4. An interdomain binding site on HIV-1 Nef interacts with PACS-1 and PACS-2 on endosomes to down-regulate MHC-I

5. Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction